Inflammatory Bowel Disease (IBD) involves acute or chronic inflammation of part or all of the digestive system, primarily including Ulcerative Colitis (UC) and Crohn's Disease - autoimmune inflammatory conditions of the colon and small intestine.
The major difference between the two diseases is the location and nature of the inflammatory changes.
Crohn's Disease can affect any part of the G.I. tract although a majority of conditions start in the terminal ileum. The condition affects the whole bowel wall characterized by transmural ulcers.
UC is restricted to the large intestine and rectum affecting the mucosa.
In both conditions, and IBD generally, there is a significant increase in pro-inflammatory cytokines (e.g. TNF-alpha, IFN-gamma, IL-17 and IL-23).
Washington Biotechnology, Inc. (WBI) has many years of experience with In Vivo TNBS-induced and Indomethacin-induced rodent models with reliable results for both prophylactic and therapeutic dosing.
Disease treatments are evaluated by:
- Colon lengths and weights
- Colon tissue scores
- Gross necropsy observations
Optional:
- Cytokine Analysis on homogenized tissue and/or serum
- Dose-response evaluation
- Statistical analysis
- Histopathology: inflammation and necrosis scores
The TNBS model produces strong inflammatory effects throughout the colon and small intestine. The IND model produces effects associated primarily in the small intestine so this model is also referred to as Small Intestine Disease (SID) model.
Results for In Vivo Scoring and Measurements, with statistical analysis, are available within 2 weeks of order - including a detailed Final Report assessing treatment efficacy.
Further analysis (e.g. histopathology) is available in an additional 2-3 weeks.
To discuss a study you are considering and request a Draft Protocol and Quotation please contact us.
